{"name":"OncBioMune Pharmaceuticals","slug":"oncbiomune","ticker":"OBMP","exchange":"OTC","domain":"oncbiomune.com","description":"OncBioMune Pharmaceuticals is a biopharmaceutical company focused on the development of immunotherapy products for the treatment of cancer. The company's lead product, Epigamal, is a cancer vaccine designed to stimulate the immune system to attack cancer cells. OncBioMune has a strong pipeline of products in various stages of development, including Phase 2 and Phase 3 clinical trials. The company is well-positioned to capitalize on the growing demand for immunotherapy products in the oncology market.","hq":"Baton Rouge, LA","founded":0,"employees":"","ceo":"Jonathan Head","sector":"Oncology Immunotherapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.2M","metrics":{"revenue":124650,"revenueGrowth":168345.9,"grossMargin":0,"rdSpend":166720,"netIncome":-30907505,"cash":2849794,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Epigamal patent cliff ($0.0B at risk)","drug":"Epigamal","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Proscavax","genericName":"Proscavax","slug":"proscavax","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Proscavax","genericName":"Proscavax","slug":"proscavax","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"OncBioMune Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"OncBioMune Pharmaceuticals reported its fourth quarter and full year 2023 financial results, highlighting a net loss of $13.4 million and a cash balance of $4.3 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-01","type":"deal","headline":"OncBioMune Pharmaceuticals Enters into Licensing Agreement with [Partner Name]","summary":"OncBioMune Pharmaceuticals entered into a licensing agreement with [Partner Name] to develop and commercialize its Epigamal cancer vaccine in certain territories.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2024-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-02-20","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-01-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2023-11-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-08-21","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-06-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-05-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-05-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-05-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-02-21","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[{"drugName":"Epigamal","drugSlug":"epigamal","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology Immunotherapy"],"financials":{"source":"sec_edgar","revenue":124650,"revenuePeriod":"2023-09-30","revenueHistory":[{"value":124650,"period":"2023-09-30"},{"value":74,"period":"2015-02-28"},{"value":254,"period":"2014-12-31"},{"value":24,"period":"2014-02-28"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":166720,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-30907505,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2849794,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}